NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$24.42
+0.48 (+2.01%)
Close of Nov 06, 2026 · end-of-day data
PRVA 8-K filings in 2026
Every material Form 8-K Privia Health Group filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Privia Health reported third-quarter 2026 revenue of $657.0 million, up 13.2% from a year earlier, and net income attributable to the company of $13.5 million, up from $6.9 million. The company raised its full-year 2026 guidance, including Adjusted EBITDA of $154 million to $157 million, up from the initial range of $145 million to $155 million. It also agreed to acquire American Choice Healthcare MSSP for approximately $36 million in cash and will exit its Montana partnership effective January 2027.
Q3 2026 total revenue was $657.0 million, up from $580.4 million; diluted net income per share was $0.10, up from $0.05.
Updated FY 2026 Adjusted EBITDA guidance is $154 million to $157 million, versus initial guidance of $145 million to $155 million given February 27, 2026.
Updated FY 2026 GAAP revenue guidance is $2,500 million to $2,550 million, versus initial guidance of $2,350 million to $2,450 million.
Cash and cash equivalents were $446.3 million at September 30, 2026, with no debt; the company expects at least $520 million in year-end cash including the acquisition.
Privia Health Group's board elected Opella Ernest, M.D., a former HCSC executive, as a Class III director effective September 1, 2026, and named her to the Compliance Committee. The change adds a director to the board and carries a $200,000 grant-date value equity award, but the filing does not describe any financial results or operational impact.
Dr. Ernest was elected by the board on August 12, 2026, effective September 1, 2026.
She was appointed to the Compliance Committee effective September 1, 2026.
Non-employee director pay includes an annual cash retainer and restricted stock units with a $200,000 grant-date fair market value.
Dr. Ernest is currently President, HCSC Markets at Health Care Service Corporation, a role held since 2023.
Privia Health Group reported second-quarter 2026 revenue of $632.6 million, up 21.4% from a year earlier, and net income attributable to the company of $9.0 million, up from $2.7 million. The company also raised its full-year 2026 guidance for all key financial metrics, including Adjusted EBITDA of $145 million to $155 million, which indicates improved profitability expectations for shareholders.
Q2 2026 revenue was $632.6 million, up 21.4% from $521.2 million in Q2 2025.
Q2 2026 net income attributable to Privia was $9.0 million, or $0.07 per share, versus $2.7 million, or $0.02 per share, a year earlier.
Q2 2026 Adjusted EBITDA was $37.4 million, up 29.1% from $29.0 million.
Updated full-year 2026 guidance includes Adjusted EBITDA of $145 million to $155 million and GAAP revenue of $2.35 billion to $2.45 billion.
Shawn Morris resigned from Privia Health Group's Board of Directors and its Compliance Committee, effective immediately, on July 6, 2026. The company said the resignation was not due to any disagreement over its operations, policies, or practices.
Resignation effective July 6, 2026, with immediate effect
Morris left the Board and the Compliance Committee of the Board
Company states no disagreement on operations, policies, or practices
Privia Health reported first-quarter 2026 revenue of $603.8 million, up 25.8% from a year earlier, and adjusted EBITDA of $36.7 million, up 36.3%. GAAP net income attributable to the company fell to $3.1 million from $4.2 million, while non-GAAP adjusted net income rose 22.3% to $24.3 million. The company kept most full-year 2026 guidance unchanged and raised its attributed lives range.
Total revenue was $603.8 million versus $480.1 million, up 25.8%.
Net income attributable to Privia Health was $3.1 million, or $0.02 per share, versus $4.2 million, or $0.03 per share, a year earlier.
Non-GAAP adjusted net income per diluted share was $0.19 versus $0.16; adjusted EBITDA was $36.7 million versus $26.9 million.
Full-year 2026 guidance for GAAP revenue ($2,350 million to $2,450 million) and adjusted EBITDA ($145 million to $155 million) was unchanged; attributed lives guidance was raised to 1,600,000 to 1,625,000 from 1,550,000 to 1,600,000.
Privia Health reported fourth-quarter and full-year 2025 results, with Q4 revenue of $541.2 million, up 17.4% from a year earlier, and full-year revenue of $2.12 billion, up 22.3%. The company also issued 2026 guidance calling for GAAP revenue of $2.35 billion to $2.45 billion and Adjusted EBITDA of $145 million to $155 million, compared with $125.5 million in 2025.
Q4 2025 net income attributable to Privia was $9.2 million, versus $4.4 million in Q4 2024; full-year net income was $22.9 million, up 59.3%.
Full-year 2025 Adjusted EBITDA was $125.5 million, up 38.8%, and operating cash flow was $163.4 million, up 49.5%.
Year-end 2025 cash was $479.7 million with no debt.
2026 guidance: GAAP revenue $2,350 million to $2,450 million; Adjusted EBITDA $145 million to $155 million; about $600 million expected year-end cash.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Privia Health Group filing is on SEC EDGAR ↗. 8-K briefs of other companies →